At #BIO2025 this week! Please reach out to hear about our nucleases #hfCas12Max, RNA editors #hfCas13Y, #AI-guided base editors & #epigenetics,
or programs - spanning #CNS (#ALS, #MECP2 duplication syndrome, #Huntington's, #Alzheimer's), #DMD, and #ophthalmology (#Stargardt, #AMD, +)

Synthego and Vita Therapeutics Forge New Licensing Partnership to Enhance CRISPR Nuclease Applications Synthego and Vita Therapeutics announce a strategic licensing partnership integrating hfCas12Max CRISPR system into Vita's therapeutic programs, enhancing their development pipeline.

Synthego and Vita Therapeutics Forge New Licensing Partnership to Enhance CRISPR Nuclease Applications #USA #Redwood_City #Synthego #Vita_Therapeutics #hfCas12Max

HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed 🎉

Source: www.huidagene.com/new/news/72

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #HuidaGene #hg302 #hfCas12Max #CRISPR #cas9